Compare Novavax Inc (NVAX) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while YieldMax NVDA Option Income Strategy ETF trades at $12.57 (market cap $1.45B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| NVAX | NVDY | |
|---|---|---|
Market Cap | $1.82B | $1.45B |
Volume | 6,198,505 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $12.56 | $17.21 |
52-Week Low | $6.22 | $11.58 |
Typical Hold Time | 59 Days | 43 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
NVDY trades at $12.57, down 3.38% with a bearish technical outlook. The ETF generates weekly dividends but faces structural limitations on upside participation. Recent analyst coverage highlights concerns about declining volatility reducing option income potential. Technical indicators show bearish momentum with support at $12 and resistance at $13.
The outlook remains cautious as NVDY's high distribution yield comes at the cost of NAV erosion. While weekly dividends provide income, the fund's capped upside during NVIDIA rallies and dependence on volatility create long-term performance challenges. Investors seeking pure NVIDIA exposure may find direct ownership more attractive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
